Live Chat Support Software
800.227.0627
September 19, 2011
In response to increased demand for custom molecular and cell biology products and services, Bio-Synthesis Inc, a U.S-based biotech company, is announcing a major expansion. During the summer of 2011, BSI created a dedicated molecular lab in its 25,000 sq. ft. manufacturing facility in Dallas, Texas, adding an eighth division to BSI’s Genomics and Proteomics department. BSI representatives believe that this will allow the company to provide a wider array of integrated life science services.

“We are indeed very grateful to our loyal customers for their continued support over the 27 years since our inception in 1984,” said Dr. Miguel Castro, CEO and founder of BSI. “We are pleased to add the newly created division, Custom Protein Expression, where we will offer a one-stop solution from gene synthesis to purified protein in both prokaryotic and eukaryotic models.”

The new molecular lab is led by a team of scientists who each have over 25 years of experience in the field. Bio-Synthesis provides assistance with several steps of the protein production process, from gene synthesis, codon optimization, choice of expression vector to high-throughput protein expression.

BSI representatives report that the company is currently expanding and creating jobs, stating that the BSI remains competitive by offering innovative products and services to the scientific community. “We understand that times are tough,” said one BSI employee, "and we want to accommodate everyone’s budget. One of the benefits of an experienced staff is that it is easier for us to switch out parts of the process, offering more expensive services to customers who want them and more affordable services to customers who are feeling the pinch. A new department specifically for protein expression gives us even more flexibility.”

Bio-Synthesis Incorporated has been serving the life science community in the fields of proteomics, epigenetics, synthetic biology, carbohydrate chemistry, peptide synthesis, cell line identification and other areas since 1984, specializing in constructing such bio-conjugates as peptides, DNA, RNA and small-molecule drugs. Bio-Synthesis has one of the largest peptide synthesis facilities in the U.S. and can provide different types of synthetic DNA, peptides of over 150 residues, antibodies, analyte-specific reagents and many other products and services. Bio-Synthesis, Inc. is headquartered in Lewisville, Texas.

Integrated solutions spanning across genomics, proteomics and cell biology.
December 15, 2010
LEWISVILLE, TX., Dec. 13, 2010 – Bio-Synthesis is pleased to announce a new human cell line authentication service (called "tissue authentication" or "tissue validation" in oncology) for laboratories working with HeLa, cancer cell and other cell lines.

Cell line contamination has interfered with scientific studies for years, but only recently has it come to the community's attention. In 2007, the NCI/ADR-RES breast cancer cell line was found to be contaminated with OVCAR-8, sparking the retraction of over 300 academic papers and compromising years of work. Only months later, the NIH called for all grant applicants to address the threat of cross-contamination with cell line identification measures. Increasing numbers of journals, notably Biotechniques, Cancer Research, and In Vitro Cellular and Developmental Biology now require authentication on all cell lines used in studies submitted for publication. The FDA is even more strict, requiring cell line authentication as a condition for drug approval.

Over the years, several different teams of researchers have noted the failure of phenotype and provenance to provide reliable information: 

•Of 1211 cell lines published between 1989 and 2007, 23 percent were found to have discrepancies in p53 status (Berglind et al).

•Of 40 ostensibly thyroid cancer cell lines, 17 were found to lack unique genetic profiles, and some were confirmed as having come from colon cancer or melanoma sources (Schwepp et al).

•Among hematopoetic cell lines, 14.8 percent were found to be contaminated with other hematopoetic cell lines (Drexler et al).

Bio-Synthesis employs short tandem repeat analysis, the technique most highly recommended by the ATCC SDO, to confirm the identities of clients submitted samples. Standard cell line authentication services start as low as $95 for a profile of preextracted DNA. Complete cell line identification packages, however, include not only AmpFlSTR Identifiler profiling but PowerPlex 1.2, StemElite, and High-Resolution Luminex HLA DNA Genotyping. In-depth services include comparison of the client's cell line to a known sample, blind analysis of the client's cell line without any preexisting knowledge of its purported origin, comparison of the client's sample to a DNA database and and cross-contamination detection covering nine species.

Bio-Synthesis' accredited cell line testing facilities have been the home of many successful projects. Bio-Synthesis invites readers to visit www.BioSyn.com for more details on this and other services. 

Spanning Across Genomics, Proteomics, and Cell Biology.

© 2010 BIO-SYNTHESIS, INC. All rights reserved



For further information, please contact:

Heidi Fazelli, [Sales Director]

Bio-Synthesis Incorporated

(800) 227-0627

http://www.biosyn.com/?utm_source=labhoo.com&utm_medium=Don't%2B Add%2BExtra%2BVariables%3B%2BVerify%2Bwith%2BBioSynthesis%2BCell%2BLine%2BI dentification&utm_campaign=Press%2BRelease%2B15Dec%2BDon't%2BAdd% 2BExtra%2BVariables%3B%2BVerify%2Bwith%2BBioSynthesis%2BCell%2BLine%2BIdentif ication

March 03, 2010
Bio-Synthesis, Inc. announced today that the National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health (NIH), has awarded the company a 2-year, $590,000, Small Business and Innovation Research (SBIR) Phase 1 grant. The company will use the proceeds to further the development of its proprietary adjuvants or immune agonists that carry in a single molecule the various determinants needed to stimulate both innate and adaptive immunities, causing synergistic effects on T cell immunity. This synergism may stimulate an exceptional Th1 immune response with production of cytotoxic T lymphocytes (CTLs), which would be advantageous in preventive vaccines against infectious agents like HIV-1. Because of their structure, these compounds may reverse the immune tolerance associated with aging and other conditions like malnutrition; as part of the formulation of therapeutic vaccines, they could be useful in stimulating an immune response medically effective in the treatment of certain chronic infectious diseases, such as HIV-1 and hepatitis viruses B and C. Due to their ameliorative effects of tolerance, these novel agonists may have applications in therapeutic vaccines against cancer, a group of diseases closely associated with aging.

Although the HIV-1 antigens required for an effective vaccine have been identified, this virus unusually high virulence has precluded so far the development of an effective vaccine. Apparently, the result of the body’s failure to produce a timely and effective protective immunity during the brief time elapsed between the virus entry and establishment of infection, as well as the capacity of the virus to develop mechanisms to scape immune surveillance. Thus, it is evident that stimulation of a protective immunity would require novel methods to stimulate a multi-prong immune response that would include both T-cell and humoral immunities as well as the more primitive but effective arm of the immune system: the innate immunity. Furthermore, it is most likely that an effective HIV-1 vaccine should also stimulate a protective immune response at the main points of viral entry: the body’s mucosal surfaces. The proposed Bio-Synthesis immune agonists have in their structures all of the determinants needed to stimulate these different immune responses that are apparently required to mount an effective protection against HIV-1 infection.

Another important application of these immune agonists would be to improve the immune system response of the aging population, the fastest growing group worldwide, which is likely to show an increased tolerance. In the US, the elderly population over 65 years old is expected to increase from 13% in the year 2000 to about 20% by the year 2030, in effect, an increase from 35 million to about 70 million people over 65 years of age. Use of these compounds in preventive vaccines, as influenza virus vaccine, should improve their performance which can be as low as 40% in the 65+ years old population, compared to 80% or better in the young populations. A situation that may explain the fact that in the US around 90% of the annual deaths attributed to influenza, occurs in people over 65 years of age.

“We are very pleased with the decision of the grants review committee to recognize the potential merits of our technology, and with the financial support of research activities by such a prestigious institution as the NIAID,” said Dr. Dante Marciani, lead scientist. “We believe that our immune agonists would play an important role in the development of a HIV-1 vaccine as well as to be a platform for the development of a wide variety of vaccines.” 

About Bio-Synthesis:
Bio-Synthesis Inc, a closely held 25 year old biotechnology company active in the areas of proteomics, epigenetics, synthetic biology, carbohydrate chemistry, synthetic peptides and others; it specializes in constructing bio-conjugates including but not limited to peptides, DNA, RNA, small drugs and other compounds. It has one of the largest peptide synthesis facilities in the USA and can handle small and large volume projects.

As an experienced CRO, it can provide different types of synthetic DNA, long peptides of over 150 residues, antibodies, ASR (Analyte Specific Reagents) for DNA and peptide/protein based diagnostics, and a number of other services/products for the life sciences.

Ian Flynn
Office of Business Liaison,
612 East Main Street Lewisville, TX 75057
Toll Free: 1-800-227-0627 ext. 209
Phone: 972-420-8505 ext. 209
Fax: 972-420-0442
Email: collaborations@biosyn.com

February 02, 2010

RNA purification is of critical importance in the preparation of samples for use in several applications including cDNA library construction, gene expression assay, in vitro translation, microarrays, Northern blot analysis, nuclease protection assays, real-time quantitative PCR, reverse transcription PCR, RNA mapping etc. Low quality RNA may strongly compromise the experimental results of these applications which are often labor-intensive, time-consuming, and highly expensive.
However, RNA purification faces lot of challenges such as extracting high quality RNA from different types of cells and tissues, extracting RNA from scarce samples, especially in clinical settings. The most common method of RNA purification is phenol extraction. Even most of the kits currently available use a preliminary phenol extraction before further purification steps. However, the major drawback of phenol extraction is that, the RNA is contaminated with significant amounts of both DNA and polysaccharides as both can be present in the aqueous layer after phenol extraction. Both contaminants are precipitated along with RNA using ethanol or isopropanol and depending on the subsequent use of the RNA, they may affect further analyses.1 Moreover, phenol extraction is also cumbersome and hazardous to use.
Bio-Synthesis Inc. has launched the RNATotalTM Purification kit which can alleviate all challenges faced by researchers in obtaining quality RNA purification at unbelievably low price.
- RNATotal TM does not require phenol extraction step.
- It can extract total RNA including large messenger RNA (mRNA), small interfering (siRNA) RNA and microRNA from all samples.
- It can extract RNA from as little as a single cell and does not require a carrier to extract RNA.
- It can extract total RNA from all kinds of specimens including cultured cells, tissues, blood, serum, plasma, bacteria, yeast, fungi, plants and viruses.
This kit uses a proprietary resin-based technology. The kits are available in both columns as well as 96-well format.
Besides RNATotalTM Purification kit, Bio-Synthesis also has several other sample purification kits that are suited for different applications. There is also a composite kit for RNA, DNA and protein purification.

 

About Bio-Synthesis

Bio-Synthesis, Inc. is a U.S. based company providing high quality products and services for life science research, diagnostics, and therapeutic applications for over 25 years. They manufacture and market a diverse number of genomic, proteomic and cell biology products such as custom oligonucleotides, peptides, antibodies, bioconjugates, catalog peptides, antibodies and sample preparation kits. They also provide several analytical services including HLA typing, DNA testing antibodies, bioconjugation, catalog peptides, antibodies, sample preparation kits and services. Their integrated manufacturing programs enable a seamless transition from the inception of an idea through product launch to their clients. For more information on Bio-Synthesis one may call 1-800-227-0627 or visit their website: www.biosyn.com.

Reference:
Isolation and characterization of nuclei and nuclear sub fractions: David Rickwood, Anthea Messant and Dipak Patel – Subcellular Fractionation: A Practical Approach by John M. Graham, David Rickwood.

January 25, 2008
LEWISVILLE, TX- January 25, 2008 – Bio-Synthesis Inc., a closely held biotechnology company, is pleased to announce an exclusive scientific collaboration with Dr. Dante Marciani, a world renowned expert in immune agonists. Over the last 20 years, Dr. Marciani has pioneered work with proprietary immune stimulatory saponins and their semi-synthetic analogs that have immune enhancing activities. These small molecule constructs have the potential to stimulate Th1 immunity thus become an important element in preventive vaccines as well as active immunotherapy. These plant-derived glycosides and their analogs have the unique ability to stimulate antigen-specific CTL production that will seek and destroy cells carrying abnormal markers, such as viral, intracellular parasites or tumor markers. Previous work by Dr. Marciani has been effective in stimulating a protective preventive immune response in commercial products, against various pathogens, such as retroviruses. These molecules have the capacity to stimulate both humoral and cell-mediated immunity; its inclusion in vaccines may result in a safe and protective immune response against infection. The collaboration between Dr. Marciani and BioSynthesis is focused on proprietary novel glycosides that stimulate innate immunity while taking advantage of the synergistic effects between innate and adaptive immunity. In addition, the collaboration extends to proprietary compounds that down regulate Th1 immunity, an area of significance in the treatment of chronic inflammatory conditions.

About Bio-Synthesis Bio-Synthesis Inc, headquartered in Lewisville, is a closely held company that is a leader in providing integrated custom synthesis solutions for life science research worldwide. With a vision for innovation, Bio-Synthesis offers expertise in technologies from oligo synthesis such as DNA, RNA, LNA, PNA to peptides, antibody, organic synthesis and molecular reagents. BioSynthesis carries a broad line of chemical modifications, labelings, special synthesis, conjugations, arrays services and reagents for basic research, high-throughput screening and drug discovery. BSI’s staff of highly experienced and qualified chemists, biologists and immunologists has reliably and consistently provided products and services to large pharmaceuticals and universities across the country that meet the most demanding requirements for quality, turnaround and expert technical support. For more information, please call Dr. Miguel Castro, BioSynthesis’ President and CEO, 1-800-227-0627 or visit www.biosyn.com.
June 11, 2007
The Peptide Synthesis Division of Bio-Synthesis has successfully developed methods to synthesize bioconjugates, such as PNA’s linked to peptides. The hybrid molecule can be up to 60 residues in length and can be half PNA and half peptide linked together, or they can be alternating PNA residues with peptide residues. This type of bioconjugate can be used to deliver peptide sequences inside a living cell by using peptide sequences at one end that have the ability to penetrate the cell membrane and carry along a PNA, that can be targeted to a regulatory DNA sequence, then upon binding to it, it can interfere with its expression (production of a protein)

Bio-Synthesis Inc, headquartered in Lewisville, Texas is a leading biomedical manufacturer of custom peptide synthesis, polyclonal antibodies, bioconjugates, DNA oligomer, HLA/DNA typing, organic synthesis and a diverse number of bimolecular products for the biomedical/life science community worldwide since 1984. Our staff of highly experienced and qualified chemists, biologists and immunologists has reliably and consistently provided products and services to large pharmaceuticals and universities across the country that meet the most demanding requirements for quality, turnaround and expert technical support.

For more information, please call 1-800-227-0627.


We are happy to announce that Biosearch Technologies of Novato, California, have extended Bio-Synthesis Inc, of Lewisville, Texas their line of Fluorescent dyes and quenchers for use in biomedical research applications. End users who source Biosearch dyes for any purpose other than non-commercial R&D applications will still be required to contact the Biosearch Technologies Licensing Department to obtain a Commercial Use License. These dyes are chemically couple to synthetic oligonucleotides and provide an excellent means for non-radioactive detection of DNA targets. Bio-Synthesis Inc have been providing custom synthetic oligonucleotides to the biomedical research community worldwide since 1984.

Bio-Synthesis Inc. was contracted by Georgia Cosmetics, Houston ,Texas to produce a series of peptides derived from colostrum. Georgia Cosmetics have filed for patents encompassing said peptides. Colostrum is the early mother’s milk thought to be important in providing the newborn with the elements necessary to establish the immune system of the child. Dr Jersey Georgiadis a world renowned protein expert is the CEO of Georgia Cosmetics, is also marketing tablets containing related peptides and other proprietary formulation that also stimulates an adult’s immune system.

Bio-Synthesis Inc was glad to sponsor the 19th Federation of North Texas Area Scientific Conference; the main speaker Dr. MacDonald from the Biochemistry Department at UT Austin spoke on Regulation of Gene Expression at the Translational Level, this subject is novel and appealing as most gene expression control was thought to be at the transcriptional level. A Texas style BBQ followed the conference where faculty and students of both Texas Woman University and the U. of North Texas had the chance to mingle and exchange with the invited speakers. Bio-Synthesis Inc. has sponsored the Federation meetings since 1,994 and hopes to continue doing so for many years to come.

May 10, 2007
June 04, 2007
Bio-Synthesis Inc is proud to announce the recent acquisition of a sophisticated Multiple Peptide Synthesizer, the Vantage from ACT, Louisville, Kentucky. This instrument has four dispenser tips, which allows for parallel washings, decreasing cycling times for peptide assembly. The Vantage is also equipped with a heating device that allows us to conduct reactions at 80 degrees Celsius, which expedites coupling times. This unit will help us to prepare a large number of peptides (96 at a time) for applications such as peptide micro arrays and discovery scale peptides; where researchers need small quantities (milligram or less), but in large numbers.

Bio-Synthesis Inc, headquartered in Lewisville, Texas is a leading biomedical manufacturer of custom peptide synthesis, polyclonal antibodies, bioconjugates, DNA oligomer, HLA/DNA typing, organic synthesis and a diverse number of bimolecular products for the biomedical/life science community worldwide since 1984. Our staff of highly experienced and qualified chemists, biologists and immunologists has reliably and consistently provided products and services to large pharmaceuticals and universities across the country that meet the most demanding requirements for quality, turnaround and expert technical support.

For more information, please call 1-800-227-0627. 

June 01, 2007
Bio-Synthesis has released an updated description for peptide synthesis; this allows peptide researchers to get a view of the broad spectrum of our capabilities. Peptides are complex molecules and each peptide sequence is unique with regard to its chemical and physical properties. Peptides are synthesized by the solid-phase method using Fmoc chemistry on an Omega 396 multiple peptide synthesizer from Advanced ChemTech. The Core also uses an Applied Biosystems Model 431A Synthesizer for longer peptides. Synthesis is carried out at 50 µmole, 100 µmole or 250 µmole scales. On an average, a synthesis scale of 100 µmoles will yield about 50-70 mg of a 10-residue peptide and 100-150 mg of a 20-residue peptide depending on the substitution rating of the resin. The peptide synthesis service provides a complete spectrum of services that include, synthesis, cleavage, HPLC purification, peptide modifications, cyclization and mass analysis for quality assurance. Before submitting your peptide sequences to the Core, it is advisable to consider the following:

* Every peptide sequence synthesized is a unique one. Some peptides sequences are difficult to synthesize although, we attempt to synthesize every peptide sequence.
* Peptides with multiple cysteines, methionine, arginine and tryptophan residues can often be difficult to synthesize.
* Avoid a proline residue at the C-terminal of the peptide.
* The peptide will be de-protected and cleaved from the resin with 82.5-90% trifluoroacetic acid, partially purified, and lyophilized. The lyophilized material will be provided as a "crude" preparation. Turnaround time is about ten days to three weeks depending on the length of the peptide and purity level. When requested, the peptide will be purified further (see below).
Bio-Synthesis is one of the top leaders in the field of Custom Oligos and Peptide synthesis, providing high quality, efficient custom DNA and Peptides to the entire Biomedical Community since 1984. Bio-Synthesis manufactures custom peptides, oligos, antibodies, organic synthesis, analytical services and more.
For further questions please feel free to contact Bio-Synthesis at 1-800-227-0627 or visit us at www.biosyn.com.
May 30, 2007
Bio-Synthesis Inc. senior scientists Drs Jianhua Ye and Miguel Castro completed the synthesis of a new kind of modified DNA. Normally there is a phosphodiester backbone linking the nucleotides in a DNA strand, however, these diester bonds are susceptible to degradation by DNA’ses, present in living cells. One way to extend the half life of DNA is by modifying the phosphodiester backbone. In this work four monomers were constructed, which upon chemical coupling produce a peptide like backbone which is unaffected by nucleases, thereby increasing the half life of these molecules and consequently extending its intended activity.

Bio-Synthesis Inc, headquartered in Dallas, Texas is a leading biomedical manufacturer of custom peptide synthesis, polyclonal antibodies, bioconjugates, DNA oligomer, HLA/DNA typing, organic synthesis and a diverse number of bimolecular products for the biomedical/life science community worldwide. Our staff of highly experienced and qualified chemists, biologists and immunologists has reliably and consistently provided products and services to large pharmaceuticals and universities across the country that meet the most demanding requirements for quality, turnaround and expert technical support.

Bio-Synthesis Inc was the first commercial company providing DNA and peptides in 1984 and have assisted biomedical researchers (and published articles) in the design of complex bimolecular, of >600,000 peptides used in a variety of fields including but not limited to cancer, apoptosis, signal transduction, cell cycle regulation, genomic sequencing, microarrays, epitope mapping, and HLA typing. We specialize in custom peptide synthesis from small to large scale and we can help you design the optimal peptides for your research needs at the most competitive price and the highest quality. We have capabilities to synthesize over 500 peptides simultaneously with over 22 years of experienced manufacturing. We believe our quality control and speed is unmatched in the industry. Our organic synthesis divisions have successfully completed a number of projects with various biotechnology companies. Furthermore, Bio-Synthesis Inc. is accredited by the AABB (American Association of Blood Banks) to conduct human genetic analysis. Bio-Synthesis continues to be the worldwide leader for quality custom synthesis.

For more information, please call 1-800-227-0627.

May 29, 2007
The DNA Synthesis Division of Bio-Synthesis Inc is proud to announce yet another custom service: Mini Gene Synthesis. With the capability to synthesize 100-200 bases long oligonucleotides, BSI can put small genes together. A small gene can be defined as one that encodes for 30-60 residues in length. The ability to chemically synthesize proves very useful to the biomedical researcher that studies control of gene expression. A mini gene can code for a peptide that can be an antagonist to a regulatory protein. BSI can deliver mini genes in about 5-7 days.

Bio-Synthesis Inc, headquartered in Dallas, Texas is a leading biomedical manufacturer of custom peptide synthesis, polyclonal antibodies, bioconjugates, DNA oligomer, HLA/DNA typing, organic synthesis and a diverse number of bimolecular products for the biomedical/life science community worldwide. Our staff of highly experienced and qualified chemists, biologists and immunologists has reliably and consistently provided products and services to large pharmaceuticals and universities across the country that meet the most demanding requirements for quality, turnaround and expert technical support.

Bio-Synthesis Inc was the first commercial company providing DNA and peptides in 1984 and have assisted biomedical researchers (and published articles) in the design of complex bimolecular, of >600,000 peptides used in a variety of fields including but not limited to cancer, apoptosis, signal transduction, cell cycle regulation, genomic sequencing, microarrays, epitope mapping, and HLA typing. We specialize in custom peptide synthesis from small to large scale and we can help you design the optimal peptides for your research needs at the most competitive price and the highest quality. We have capabilities to synthesize over 500 peptides simultaneously with over 22 years of experienced manufacturing. We believe our quality control and speed is unmatched in the industry. Our organic synthesis divisions have successfully completed a number of projects with various biotechnology companies. Furthermore, Bio-Synthesis Inc. is accredited by the AABB (American Association of Blood Banks) to conduct human genetic analysis. Bio-Synthesis continues to be the worldwide leader for quality custom synthesis.

For more information, please call 1-800-227-0627.

May 21, 2007
Bio-Synthesis Inc CEO Miguel Castro attended and formed part of the Collin County College Biotechnology (CCCB) Advisory Board; the mission of the Board is to advise the College in ways to improve the curriculum and to establish cooperative programs where the CCCB students /graduates perform internships with local biotech companies, where they can learn valuable hands on experience and give the local companies a chance to observe the performance of the students for possible permanent hiring. A number of local universities faculty form part of the board; these universities include: Texas A&M University, UT Southwestern, UT Dallas, University of North Texas Health Science Center and other members are senior officers of local biotech companies. The CCCB campus is located in Collin County; Bio-Synthesis Inc is located in the adjacent county of Denton.

Bio-Synthesis is one of the top leaders in the field of Custom DNA and Peptide synthesis, providing high quality, efficient custom DNA and Peptides to the entire Biomedical Community since 1984. Bio-Synthesis services include custom peptides, oligos, antibodies, organic synthesis, analytical services and more.

For further questions please feel free to contact Bio-Synthesis at 1-800-227-0627.

May 15, 2007
Bio-Synthesis has released an updated description for peptide synthesis; this allows peptide researchers to get a view of the broad spectrum of our capabilities:
Peptides are complex molecules and each peptide sequence is unique with regard to its chemical and physical properties. Peptides are synthesized by the solid-phase method using Fmoc chemistry on an Omega 396 multiple peptide synthesizer from Advanced ChemTech. The Core also uses an Applied Biosystems Model 431A Synthesizer for longer peptides. Synthesis is carried out at 50 µmole, 100 µmole or 250 µmole scales. On an average, a synthesis scale of 100 µmoles will yield about 50-70 mg of a 10-residue peptide and 100-150 mg of a 20-residue peptide depending on the substitution rating of the resin. The peptide synthesis service provides a complete spectrum of services that include, synthesis, cleavage, HPLC purification, peptide modifications, cyclization and mass analysis for quality assurance. Before submitting your peptide sequences to the Core, it is advisable to consider the following:

* Every peptide sequence synthesized is a unique one. Some peptides sequences are difficult to synthesize although, we attempt to synthesize every peptide sequence. 
* Peptides with multiple cysteines, methionine, arginine and tryptophan residues can often be difficult to synthesize. 
* Avoid a proline residue at the C-terminal of the peptide. 
* The peptide will be de-protected and cleaved from the resin with 82.5-90% trifluoroacetic acid, partially purified, and lyophilized. The lyophilized material will be provided as a "crude" preparation. Turnaround time is about ten days to three weeks depending on the length of the peptide and purity level. When requested, the peptide will be purified further (see below).


Bio-Synthesis is one of the top leaders in the field of Custom DNA and Peptide synthesis, providing high quality, efficient custom DNA and Peptides to the entire Biomedical Community since 1984. Bio-Synthesis services include custom peptides, oligos, antibodies, organic synthesis, analytical services and more.

For further questions please feel free to contact our Bio-Synthesis at 1-800-227-0627